Iktos
Iktos is a deep learning technology platform focused on new drug design and discovery.
About Iktos
Iktos is a French scale-up company specializing in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos’ proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI).
Company Facts
- Headquarters
- Paris
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00051_00100
- Funding Stage
- early_stage_venture
- Total Funding
- $19,034,011
- Last Funding Type
- grant
- Last Funding Date
- 2025-02-20
- Website
- iktos.ai
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Chemical, Health Care, Pharmaceutical
Social Links
Canonical: https://fsome.com/organization/iktos-102731 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.